Adage Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Adage Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-322,000	Closed	-$21.9M	–	779
2018 Q1	$21.9M	Sell	322,000 -1,900,500	-86%	-$142M	0.05%	376
2017 Q4	$220M	Sell	2,222,500 -327,500	-13%	-$36.6M	0.5%	45
2017 Q3	$305M	Sell	2,550,000 -800,000	-24%	-$74.4M	0.74%	23
2017 Q2	$293M	Sell	3,350,000 -2,336,668	-41%	-$131M	0.72%	24
2017 Q1	$212M	Hold	5,686,668	–	–	0.53%	37
2016 Q4	$175M	Hold	5,686,668	–	–	0.48%	47
2016 Q3	$381M	Hold	5,686,668	–	–	1.05%	7
2016 Q2	$169M	Hold	5,686,668	–	–	0.46%	60
2016 Q1	$167M	Hold	5,686,668	–	–	0.45%	60
2015 Q4	$446M	Hold	5,686,668	–	–	1.17%	4
2015 Q3	$429M	Hold	5,686,668	–	–	1.19%	5
2015 Q2	$664M	Hold	5,686,668	–	–	1.66%	2
2015 Q1	$1.34B	Hold	5,686,668	–	–	3.27%	1
2014 Q4	$1.08B	Hold	5,686,668	–	–	2.63%	1
2014 Q3	$1.36B	Hold	5,686,668	–	–	3.35%	1
2014 Q2	$375M	Hold	5,686,668	–	–	0.97%	10
2014 Q1	$592M	Hold	5,686,668	–	–	1.62%	2
2013 Q4	$589M	Buy	5,686,668 +444,149	+8%	+$26.1M	1.56%	2
2013 Q3	$281M	Hold	5,242,519	–	–	0.81%	17
2013 Q2	$233M	Buy	+5,242,519	New	+$185M	0.72%	23

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Adage Capital Partners's PBYI Position: Q2 2018 in Review

Adage Capital Partners sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 322,000 shares — an estimated $21.9M sold.

Adage Capital Partners first reported a position in PBYI in Q2 2013 and held it in 20 quarters. The position peaked at $1.36B in Q3 2014. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

Adage Capital Partners reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
Adage Capital Partners sold 322,000 Puma Biotechnology shares in Q2 2018, an estimated $21.9M.
Adage Capital Partners first reported a position in Puma Biotechnology in Q2 2013 and held it in 20 quarters.
Adage Capital Partners's Puma Biotechnology position peaked at $1.36B in Q3 2014.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Adage Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.